Praxis Precision Medicines, Inc. (PRAX)
295.51
+8.60
(+3.00%)
USD |
NASDAQ |
Oct 02, 16:00
295.87
+0.36
(+0.12%)
Pre-Market: 20:00
Praxis Precision Medicines Enterprise Value : 7.492B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 7.492B |
| October 01, 2026 | 7.252B |
| September 30, 2026 | 7.373B |
| September 29, 2026 | 7.087B |
| September 28, 2026 | 7.217B |
| September 25, 2026 | 7.081B |
| September 24, 2026 | 7.109B |
| September 23, 2026 | 7.118B |
| September 22, 2026 | 7.636B |
| September 21, 2026 | 7.586B |
| September 18, 2026 | 7.588B |
| September 17, 2026 | 7.910B |
| September 16, 2026 | 7.868B |
| September 15, 2026 | 7.978B |
| September 14, 2026 | 8.470B |
| September 11, 2026 | 8.583B |
| September 10, 2026 | 8.694B |
| September 09, 2026 | 8.882B |
| September 08, 2026 | 9.083B |
| September 04, 2026 | 9.064B |
| September 03, 2026 | 9.157B |
| September 02, 2026 | 9.223B |
| September 01, 2026 | 9.109B |
| August 31, 2026 | 9.022B |
| August 28, 2026 | 8.867B |
| Date | Value |
|---|---|
| August 27, 2026 | 9.512B |
| August 26, 2026 | 9.777B |
| August 25, 2026 | 9.516B |
| August 24, 2026 | 9.517B |
| August 21, 2026 | 9.738B |
| August 20, 2026 | 9.420B |
| August 19, 2026 | 10.02B |
| August 18, 2026 | 9.567B |
| August 17, 2026 | 9.750B |
| August 14, 2026 | 9.483B |
| August 13, 2026 | 9.529B |
| August 12, 2026 | 10.03B |
| August 11, 2026 | 9.591B |
| August 10, 2026 | 9.487B |
| August 07, 2026 | 9.314B |
| August 06, 2026 | 9.576B |
| August 05, 2026 | 8.154B |
| August 04, 2026 | 7.899B |
| August 03, 2026 | 7.771B |
| July 31, 2026 | 7.836B |
| July 30, 2026 | 7.834B |
| July 29, 2026 | 7.367B |
| July 28, 2026 | 7.501B |
| July 27, 2026 | 8.059B |
| July 24, 2026 | 8.324B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Insmed, Inc. | 23.84B |
| Vertex Pharmaceuticals, Inc. | 121.99B |
| BridgeBio Pharma, Inc. | 15.82B |
| Mirum Pharmaceuticals, Inc. | 5.695B |
| ACADIA Pharmaceuticals, Inc. | 2.551B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -83.72M |
| Total Expenses (Quarterly) | 83.72M |
| EPS Diluted (Quarterly) | -2.874 |
| Earnings Yield | -4.38% |
| Normalized Earnings Yield | -4.380 |